STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Clinical trials for STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to supercharge immune system to fight cancer before surgery
Disease control Recruiting nowThis study is testing if adding a new immune-boosting drug (CDX-1140) to an existing immunotherapy (cemiplimab) works better before surgery for advanced head and neck cancer. The goal is to shrink the tumor more effectively, which could lead to less extensive surgery. About 44 pa…
Matched conditions: STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New hope for advanced skin cancer: boosting immune system before surgery
Disease control Recruiting nowThis large, late-stage trial is testing if adding an immunotherapy drug (cemiplimab) before and after surgery works better than surgery alone for people with advanced, operable skin cancer. The goal is to see if this approach helps the body's immune system fight the cancer, reduc…
Matched conditions: STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Custom-Made vaccine aims to train immune system to fight advanced cancers
Disease control Recruiting nowThis study is testing a new, personalized vaccine designed to target the unique proteins on a patient's own cancer cells. It is being given alongside an existing immunotherapy drug (pembrolizumab) to see if the combination is safe and can help control advanced solid tumors that h…
Matched conditions: STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New drug aims to shield cancer patients from painful mouth sores
Symptom relief Recruiting nowThis study is testing if adding an investigational drug called BMX-001 to standard symptom care can better prevent severe mouth sores in people receiving combined chemotherapy and radiation for head and neck cancer. About 98 participants will be randomly assigned to receive eithe…
Matched conditions: STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Mar 16, 2026 15:26 UTC
-
New hope to spare cancer patients from opioid addiction during treatment
Symptom relief Recruiting nowThis large, late-stage trial is testing if a high dose of the drug gabapentin, started early, can prevent the need for strong opioid painkillers in patients receiving chemotherapy and radiation for head and neck cancer. The goal is to manage the severe mouth sores and pain that a…
Matched conditions: STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Mar 06, 2026 15:38 UTC